

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7552787

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT	
EFFECTIVE DATE:	09/30/2013	
SEQUENCE:	1	
CONVEYING PARTY DATA		
Name		Execution Date
QUEST DIAGNOSTICS INVESTMENTS INCORPORATED		08/12/2022
RECEIVING PARTY DATA		
Name:	ENTERIX INC.	
Street Address:	236 FERNWOOD AVE	
City:	EDISON	
State/Country:	NEW JERSEY	
Postal Code:	08837	
PROPERTY NUMBERS Total: 2		
Property Type	Number	
Patent Number:	8198036	
Patent Number:	8497136	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	jillian.curry@clinicalgenomics.com	
Correspondent Name:	ENTERIX INC.	
Address Line 1:	236 FERNWOOD AVE	
Address Line 4:	EDISON, NEW JERSEY 08837	
ATTORNEY DOCKET NUMBER:	PICASSO	
NAME OF SUBMITTER:	JILLIAN CURRY	
SIGNATURE:	/Jillian Curry/	
DATE SIGNED:	09/22/2022	
Total Attachments: 2		
source=Quest - Clinical Genomics - Confirmatory Assignment and Quitclaim_executed#page1.tif		
source=Quest - Clinical Genomics - Confirmatory Assignment and Quitclaim_executed#page2.tif		

CONFIRMATORY ASSIGNMENT AND QUITCLAIM

WHEREAS, Quest Diagnostics Investments LLC (f/k/a Quest Diagnostics Investments Incorporated), a Delaware limited liability company ("**ASSIGNOR**") may have owned U.S. Patent No. 8,198,036 and U.S. Patent No. 8,497,136 (collectively, the "**SUBJECT PATENTS**"); and

WHEREAS, Clinical Genomics Pty Ltd (ACN 119 063 222), is an Australian corporation with its principal place of business at of 11 Julius Avenue, North Ryde, 2113 ("**ASSIGNEE**"); and

WHEREAS, pursuant to and as set forth in a Stock Purchase Agreement dated September 30, 2013 and executed by and among Quest Diagnostics Incorporated (a Delaware corporation and ASSIGNOR's parent company), Enterix Inc. (a Delaware corporation) and Clinical Genomics Technologies Pty Ltd (an Australian corporation and ASSIGNEE's parent company), Enterix Inc. sold to Clinical Genomics Technologies Pty Ltd all of the shares of Enterix Pty Limited (ACN 079 851 308), an Australian corporation, and Enterix (Australia) Pty Limited (ACN 093 240 512), an Australian corporation (such Stock Purchase Agreement, the "**STOCK PURCHASE AGREEMENT**"); and

WHEREAS, in view of the STOCK PURCHASE AGREEMENT, ASSIGNOR and ASSIGNEE are desirous of confirming that ASSIGNEE or an affiliate of ASSIGNEE has acquired all right, title, and interest in and to the SUBJECT PATENTS, as of the date of the STOCK PURCHASE AGREEMENT.

NOW, THEREFORE, in consideration of the premises hereof and the mutual promises contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

ASSIGNOR hereby irrevocably assigns, transfers, conveys, remises, releases, and

quitclaims forever to ASSIGNEE any and all right, title, and interest in and to the SUBJECT PATENTS that ASSIGNOR has or may have, with effect as of September 30, 2013, i.e., the date of the STOCK PURCHASE AGREEMENT.

IN TESTIMONY WHEREOF, ASSIGNOR, as represented by one of its officers, has signed this instrument this 12th day of August, 2022.

Quest Diagnostics Investments Incorporated

Wayne Brown
Signature

Wayne Benjamin Brown

Name

Deputy General Counsel & Chief
Intellectual Property Officer

Title